<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241137</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489H2301</org_study_id>
    <nct_id>NCT00241137</nct_id>
  </id_info>
  <brief_title>A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg</brief_title>
  <official_title>A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this was to evaluate valsartan 320mg compared to valsartan 160 mg in terms of
      blood pressure reduction in a patient population of mild to moderate hypertensives
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline diastolic blood pressure after 4 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline systolic blood pressure after 4 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline diastolic and systolic blood pressure in patients with a diastolic blood pressure greater than or equal to 90 mmHg at randomization after 4 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events at each study visit for 4 weeks</measure>
  </secondary_outcome>
  <enrollment type="Actual">3790</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â€¢ Male or female age between 18-80 years of age, inclusive

               -  Diagnosed at enrollment (visits 2) to be mild to moderate hypertensive with a
                  MSDBP &gt;= 95 and =&lt; 109 mmHg for non treated patients.

               -  Previously treated patients should have a MSDBP =&lt; 109 mmHg at visit 1 and a
                  MSDBP &gt;= 95 and =&lt; 109 mmHg at visit 2.

               -  Written informed consent to participate in the study prior to any study
                  procedures

               -  Ability to communicate and comply with all study requirements

        Exclusion Criteria:

          -  Severe hypertension (grade 3 of WHO classification; &gt;= 110 mmHg diastolic and/or &gt;=
             180 mmHg systolic).

          -  Malignant hypertension

          -  Inability to discontinue all prior anti-hypertensive medications safely for a period
             of 2 weeks, as required by the protocol.

          -  Known history of proteinuria (greater than 0.3 gram per day)

          -  Female patients who are not either post-menopausal for one year or surgically sterile,
             and who are not using effective contraceptive methods such as barrier method with
             spermicidal or an intra-uterine device. Oral contraceptive use is not allowed.

          -  Known Keith-Wagener grade III or IV hypertensive retinopathy.

          -  History of hypertensive encephalopathy or cerebrovascular accident at anytime prior to
             Visit 1.

          -  Transient ischemic cerebral attack during the last 12 months prior to Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceutical</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Investigative Centers</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2005</study_first_posted>
  <last_update_submitted>November 22, 2011</last_update_submitted>
  <last_update_submitted_qc>November 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

